trial · primary record
Antigen-specific IgT cells
Glioblastoma Multiforme of Brain
| Phase | Phase 1 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2026-07-31 |
| Primary endpoint | Safety of infusion of autologous IgT cells with cyclophosphamide and fludarabine as lymphodepleting chemotherapy in patients with recurrent glioblastoma using the NCI CTCAE V4.0 criteria. |
| Registry ID | NCT03170141 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:42:51.313Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03170141
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.